Prognostic significance of prostaglandin E2 production in fresh tissues of head and neck cancer patients
Article first published online: 18 JUL 2006
Copyright © 1995 Wiley Periodicals, Inc., A Wiley Company
Head & Neck
Volume 17, Issue 2, pages 108–113, March/April 1995
How to Cite
Snyderman, C. H., Milanovich, M., Wagner, R. L. and Johnson, J. T. (1995), Prognostic significance of prostaglandin E2 production in fresh tissues of head and neck cancer patients. Head Neck, 17: 108–113. doi: 10.1002/hed.2880170206
- Issue published online: 18 JUL 2006
- Article first published online: 18 JUL 2006
- Manuscript Accepted: 19 JUL 1994
- National Cancer Institute, the Mary Hillman Jennings Foundation. Grant Number: 5 R29 CA53486-02
- John R. McCune Charitable Trust Foundation
Background. Immunosuppressive prostaglandins may play a role in the biologic behavior of head and neck cancer. Increased levels of prostaglandin E2 (PGE2) have been measured in squamous cell carcinoma of the head and neck (SCCHN).
Methods. To address this question, tissue levels of PGE2 were measured in tumor tissues, normal mucosa, and lymph nodes of 37 patients undergoing tumor resections. Tissue specimens were placed in culture media, and levels of PGE2 released into the supernatant were measured by radioimmunoassay.
Results. Tissue levels of PGE2 were significantly greater in tumor and normal mucosal tissues compared to lymph nodes (p = 0.0003). There was no difference between metastatic and tumor-free lymph nodes. Although tumor tissue levels of PGE2 were not associated with tumor stage, increased levels of PGE2 were associated with increased 2-year disease-free survival (p = 0.02).
Conclusions. Although PGE2 may have adverse effects on local immune function in tumor tissues, improved survival of patients with increased local PGE2 production may be indicative of an enhanced immunologic response to the tumor which has a favorable impact on outcome. © 1995 Jons Wiley & Sons, Inc.